FDA considering expanded melanoma use for BMS' Yervoy
This article was originally published in Scrip
Executive Summary
The FDA has accepted for review Bristol-Myers Squibb's supplemental biologics license application (sBLA) for Yervoy (ipilimumab) as an adjuvant treatment for patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection.